{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:37:43Z","timestamp":1792111063173,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Eicosapentaenoic acid in its ethyl ester form is the single active component of icosapent ethyl (IPE). This study was a phase III, multi-center trial assessing the safety and efficiency of IPE for treating very high triglyceride (TG) in a Chinese cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients having TG levels (5.6\u201322.6\u00a0mmol\/L) were enrolled and randomly assigned to receive a treatment of oral intake of 4\u00a0g or 2\u00a0g\/day of IPE, or placebo. Before and after 12\u00a0weeks of treatment, TG levels were assessed and the median was calculated to determine the change between the baseline and week 12. In addition to examining TG levels, the impact of such treatments on other lipid changes was also investigated. The official Drug Clinical Trial Information Management Platform has registered this study (CTR20170362).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Random assignments were performed on 373 patients (mean age 48.9\u00a0years; 75.1% male). IPE (4\u00a0g\/day) lowered TG levels by an average of 28.4% from baseline and by an average of 19.9% after correction for placebo (95% CI: 29.8%-10.0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). In addition, plasma concentration of non-high-density lipoprotein cholesterol (non-HDL-C), very low-density lipoprotein (VLDL) cholesterol, and VLDL-TG remarkedly reduced after IPE (4\u00a0g\/day) treatment by a median of 14.6%, 27.9%, and 25.2%, respectively compared with participants in placebo group. Compared to the placebo, neither 4 nor 2\u00a0g of IPE daily elevated LDL-C levels with statistical significance. IPE was well tolerated by all the treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IPE at 4\u00a0g\/day dramatically lowered other atherogenic lipids without a noticeable increase in LDL-C, thereby decreasing TG levels in an exceptionally high-TG Chinese population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-023-01838-8","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T07:02:18Z","timestamp":1686380538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China"],"prefix":"10.1186","volume":"22","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghai","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junbo","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"key":"1838_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ecl.2017.11.001","volume":"47","author":"FJ Pasquel","year":"2018","unstructured":"Pasquel FJ, Gregg EW, Ali MK. The evolving epidemiology of atherosclerotic cardiovascular disease in people with diabetes. Endocrinol Metab Clin North Am. 2018;47:1\u201332.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1838_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, Tokgozoglu L, Lewis EF. Atherosclerosis. Nat Rev Dis Primers. 2019;5:56.","journal-title":"Nat Rev Dis Primers"},{"key":"1838_CR3","doi-asserted-by":"publisher","first-page":"k835","DOI":"10.1136\/bmj.k835","volume":"360","author":"A Ryan","year":"2018","unstructured":"Ryan A, Heath S, Cook P. Dyslipidaemia and cardiovascular risk. BMJ. 2018;360:k835.","journal-title":"BMJ"},{"key":"1838_CR4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459\u201372.","journal-title":"Eur Heart J"},{"key":"1838_CR5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289\u201397.","journal-title":"JAMA"},{"key":"1838_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"1838_CR7","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1838_CR8","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"1838_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-011-0219-7","volume":"14","author":"UK Sampson","year":"2012","unstructured":"Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep. 2012;14:1\u201310.","journal-title":"Curr Atheroscler Rep"},{"key":"1838_CR10","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2337\/dbi19-0007","volume":"69","author":"A Chait","year":"2020","unstructured":"Chait A, Ginsberg HN, Vaisar T, Heinecke JW, Goldberg IJ, Bornfeldt KE. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes. 2020;69:508\u201316.","journal-title":"Diabetes"},{"key":"1838_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","volume":"140","author":"NA Marston","year":"2019","unstructured":"Marston NA, Giugliano RP, Im K, Silverman MG, O\u2019Donoghue ML, Wiviott SD, Ference BA, Sabatine MS. Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials. Circulation. 2019;140:1308\u201317.","journal-title":"Circulation"},{"key":"1838_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1838_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547\u201363.","journal-title":"Circ Res"},{"key":"1838_CR14","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","volume":"324","author":"SJ Nicholls","year":"2020","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268\u201380.","journal-title":"JAMA"},{"key":"1838_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203\u201312.","journal-title":"N Engl J Med"},{"key":"1838_CR16","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"A-H Investigators","year":"2011","unstructured":"Investigators AH, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255\u201367.","journal-title":"N Engl J Med"},{"key":"1838_CR17","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Group AS, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563\u201374.","journal-title":"N Engl J Med"},{"key":"1838_CR18","doi-asserted-by":"publisher","first-page":"4721357","DOI":"10.1155\/2018\/4721357","volume":"2018","author":"R Garg","year":"2018","unstructured":"Garg R, Rustagi T. Management of hypertriglyceridemia induced acute pancreatitis. Biomed Res Int. 2018;2018:4721357.","journal-title":"Biomed Res Int"},{"key":"1838_CR19","first-page":"825","volume":"116","author":"KG Parhofer","year":"2019","unstructured":"Parhofer KG, Laufs U. The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int. 2019;116:825\u201332.","journal-title":"Dtsch Arztebl Int"},{"key":"1838_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ijcard.2017.12.069","volume":"260","author":"M Zhang","year":"2018","unstructured":"Zhang M, Deng Q, Wang L, Huang Z, Zhou M, Li Y, Zhao Z, Zhang Y, Wang L. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults: a nationally representative survey of 163,641 adults. Int J Cardiol. 2018;260:196\u2013203.","journal-title":"Int J Cardiol"},{"key":"1838_CR21","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","volume":"140","author":"AC Skulas-Ray","year":"2019","unstructured":"Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140:e673\u201391.","journal-title":"Circulation"},{"key":"1838_CR22","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/ijms19020532","volume":"19","author":"JK Innes","year":"2018","unstructured":"Innes JK, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiometabolic risk factors: a systematic review. Int J Mol Sci. 2018;19:532.","journal-title":"Int J Mol Sci"},{"key":"1838_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380:23\u201332.","journal-title":"N Engl J Med"},{"key":"1838_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","volume":"379","author":"L Bowman","year":"2018","unstructured":"Group ASC, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540\u201350.","journal-title":"N Engl J Med"},{"key":"1838_CR25","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","volume":"108","author":"HE Bays","year":"2011","unstructured":"Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682\u201390.","journal-title":"Am J Cardiol"},{"key":"1838_CR26","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","volume":"73","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. J Am Coll Cardiol. 2019;73:2791\u2013802.","journal-title":"J Am Coll Cardiol"},{"key":"1838_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11\u201322.","journal-title":"N Engl J Med"},{"key":"1838_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s12944-017-0625-0","volume":"16","author":"J Peng","year":"2017","unstructured":"Peng J, Luo F, Ruan G, Peng R, Li X. Hypertriglyceridemia and atherosclerosis. Lipids Health Dis. 2017;16:233.","journal-title":"Lipids Health Dis"},{"key":"1838_CR29","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.jacl.2012.08.007","volume":"6","author":"JB Christian","year":"2012","unstructured":"Christian JB, Arondekar B, Buysman EK, Johnson SL, Seeger JD, Jacobson TA. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg\/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450\u201361.","journal-title":"J Clin Lipidol"},{"key":"1838_CR30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","volume":"8","author":"JJ Kastelein","year":"2014","unstructured":"Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8:94\u2013106.","journal-title":"J Clin Lipidol"},{"key":"1838_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/00043798-199710000-00011","volume":"4","author":"WS Harris","year":"1997","unstructured":"Harris WS, Ginsberg HN, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4:385\u201391.","journal-title":"J Cardiovasc Risk"},{"key":"1838_CR32","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","volume":"74","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Jiao L, Tardif JC, Gregson J, Pocock SJ, Ballantyne CM, Investigators R-I. Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles. J Am Coll Cardiol. 2019;74:1159\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"1838_CR33","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","volume":"110","author":"CM Ballantyne","year":"2012","unstructured":"Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984\u201392.","journal-title":"Am J Cardiol"},{"key":"1838_CR34","doi-asserted-by":"publisher","first-page":"i1246","DOI":"10.1136\/bmj.i1246","volume":"353","author":"CE Ramsden","year":"2016","unstructured":"Ramsden CE, Zamora D, Majchrzak-Hong S, Faurot KR, Broste SK, Frantz RP, Davis JM, Ringel A, Suchindran CM, Hibbeln JR. Re-evaluation of the traditional diet-heart hypothesis: analysis of recovered data from Minnesota Coronary Experiment (1968\u201373). BMJ. 2016;353:i1246.","journal-title":"BMJ"},{"key":"1838_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/ajcn\/nqz349","volume":"112","author":"J Li","year":"2020","unstructured":"Li J, Guasch-Ferr\u00e9 M, Li Y, Hu FB. Dietary intake and biomarkers of linoleic acid and mortality: systematic review and meta-analysis of prospective cohort studies. Am J Clin Nutr. 2020;112:150\u201367.","journal-title":"Am J Clin Nutr"},{"key":"1838_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12944-017-0542-2","volume":"16","author":"S Ouchi","year":"2017","unstructured":"Ouchi S, Miyazaki T, Shimada K, Sugita Y, Shimizu M, Murata A, Kato T, Aikawa T, Suda S, Shiozawa T, et al. Decreased circulating dihomo-gamma-linolenic acid levels are associated with total mortality in patients with acute cardiovascular disease and acute decompensated heart failure. Lipids Health Dis. 2017;16:150.","journal-title":"Lipids Health Dis"},{"key":"1838_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1507\/endocrj.EJ20-0564","volume":"68","author":"T Okamura","year":"2021","unstructured":"Okamura T, Nakajima H, Hashimoto Y, Majima S, Senmaru T, Ushigome E, Nakanishi N, Hamaguchi M, Asano M, Yamazaki M. Low circulating dihomo-gamma-linolenic acid is associated with diabetic retinopathy: a cross sectional study of KAMOGAWA-DM cohort study. Endocr J. 2021;68:421\u20138.","journal-title":"Endocr J"},{"key":"1838_CR38","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.2169\/internalmedicine.0816-18","volume":"57","author":"Y Tsurutani","year":"2018","unstructured":"Tsurutani Y, Inoue K, Sugisawa C, Saito J, Omura M, Nishikawa T. Increased serum dihomo-\u03b3-linolenic acid levels are associated with obesity, body fat accumulation, and insulin resistance in Japanese patients with type 2 diabetes. Intern Med. 2018;57:2929\u201335.","journal-title":"Intern Med"},{"key":"1838_CR39","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/dc21-S010","volume":"44","author":"American Diabetes A","year":"2021","unstructured":"American Diabetes A. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S125\u201350.","journal-title":"Diabetes Care"},{"key":"1838_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s11883-020-00895-z","volume":"22","author":"X Jia","year":"2020","unstructured":"Jia X, Al Rifai M, Hussain A, Martin S, Agarwala A, Virani SS. Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well. Curr Atheroscler Rep. 2020;22:72.","journal-title":"Curr Atheroscler Rep"},{"key":"1838_CR41","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jacl.2019.10.014","volume":"13","author":"CE Orringer","year":"2019","unstructured":"Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13:860\u201372.","journal-title":"J Clin Lipidol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-023-01838-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01838-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T08:01:48Z","timestamp":1686384108000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-023-01838-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1838"],"URL":"https:\/\/doi.org\/10.1186\/s12944-023-01838-8","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"6 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial was conducted in 39 research centers in China. The research protocol adhered to the International Conference on Harmonization Guidelines for Good Clinical Practice, and regulations and directives set forth by autonomous local and\/or national ethics committees. The Helsinki Declaration was followed in conducting all procedures. Institutional review boards granted approval of the protocol, consent forms, and additional pertinent documentation. Prior to the commencement of the study, signed informed consent were provided by all patients. The registration number was CTR20170362 (available at:\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}